MedPath

Effects of Bile Acids and Bile Acid Sequestrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass

Phase 4
Completed
Conditions
Severe Obesity
Interventions
Registration Number
NCT02876484
Lead Sponsor
Hvidovre University Hospital
Brief Summary

The purpose of this study is to examine the effects of bile acid and bile acids sequestrants on GLP-1 Secretion, during a meal, in patients after Roux-en-Y gastric bypass.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
12
Inclusion Criteria
  • Uncomplicated RYGB performed minimum 3 months prior to the study.
  • Fasting plasma glucose < 7,0 mM, HbA1c < 48 mmol/mol 3 months after RYGB
Exclusion Criteria
  • Fasting plasma glucose > 7,0 mM, HbA1c > 48 mmol/mol 3 months after RYGB.
  • Dysregulated thyroid diseases, use of antithyroid treatment.
  • Late diabetic complications as retinopathy, renal insufficiency, neuropathy or previous pancreatitis.
  • Complications to RYGB. Documented reactive hypoglycaemia, severe dumping (vomiting, diarrhea, severe abdominal pain after food intake).
  • Cholecystectomy

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
PlaceboWaterMorning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM. 25 ml water
Chenodeoxycholic AcidChenodeoxycholic AcidMorning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM. Chenodeoxycholic acid (1250 mg) mixed in 25 ml yoghurt
ColesevelamColesevelamMorning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM. Colesevelam (3,75 g) dissolved in 25 ml water and mixed in 25 ml yoghurt.
Colesevelam x 2Colesevelamplus (on another study day) 3,75 g colesevelam administered the evening before the experiment. Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM. Colesevelam (3,75 g) dissolved in 25 ml water and mixed in 25 ml yoghurt.
Primary Outcome Measures
NameTimeMethod
GLP-1 secretion (evaluated by iAUC)-10, 0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes after mixed meal
Secondary Outcome Measures
NameTimeMethod
Insulin secretion-10, 0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes
PYY secretion-10, 0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes
Bile acids/FGF19 concentrations-10, 0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes
Glucose levels-10, 0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes
PCM levelsBaseline, 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240 minutes
CCK secretion0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes
Total bile acid secretion0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes
Appetite measurements (VAS-score)0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes
C-peptide secretionBaseline, 0, 5, 10, 20, 30, 45, 60, 90, 120, 180, 240 minutes
Glucagon secretionBaseline, 0, 10, 20, 30, 45, 60, 90, 120, 180, 240 minutes
GIP secretion0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes
Ghrelin0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes

Trial Locations

Locations (1)

Hvidovre University Hospital

🇩🇰

Hvidovre, Denmark

© Copyright 2025. All Rights Reserved by MedPath